Latest news with #NajatKhan
Yahoo
10-07-2025
- Business
- Yahoo
Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the . Recursion Pharmaceuticals dropped its share prices by 6.45 percent on Monday to close at $4.93 apiece as investors appeared to have booked profits following four straight days of gains. In recent news, the company unveiled Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
07-06-2025
- Business
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
07-06-2025
- Business
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-06-2025
- Business
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-05-2025
- Business
- Yahoo
AI specialist Recursion trims pipeline in latest shakeup
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. AI drug discovery specialist Recursion Pharmaceuticals is shelving three of its most advanced drug prospects in an effort to cut costs following a merger last year. Alongside its latest quarterly earnings report, the company revealed plans to halt development of drugs for cerebral cavernous malformation and neurofibromatosis type II that were in mid-stage testing. Recursion will also pause testing and attempt to license out a therapy it's been advancing for C. difficile infections. The decisions reflect Recursion's plan to focus on 'areas of high unmet need where we believe we can have the greatest impact,' said Najat Khan, the company's chief R&D officer and chief commercial officer, in a statement. Following a merger with fellow AI biotech Exscientia last year, the company has been 'proactively streamlining' its operations and 'making deliberate tradeoffs' to focus resources on its most impactful programs, Khan added. Four years ago, Recursion raised $436 million in one of the biotech sector's most lucrative initial public offerings. The company secured those funds on the promise of AI, which is seen by proponents as a way to speed up drug discovery and increase its odds of success. And in combining with Exscientia in 2024, Recursion touted a sprawling pipeline that would produce 10 near-term clinical readouts and had the potential to deliver multiple blockbusters. The company hasn't yet fulfilled its promise, though. Early clinical data for its treatment for cerebral cavernous malformation disappointed investors and, according to the company's statement Monday, the 'totality' of the results accrued since then led it to stop testing. The neurofibromatosis type II therapy is being scrapped for similar reasons, while a changing treatment landscape has reduced the need for the C. difficile drug it's been developing. To Mani Foroohar, an analyst with Leerink Partners, the pipeline cuts were 'inevitable' given the company's 'unsustainable cash burn.' The company booked a roughly $464 million net loss in 2024, following a $328 million net loss the year prior. It had $509 million in cash as of the end of March. Foroohar added in a research note Monday that Phase 2 data the company released Sunday in a condition that causes the growth of potentially dangerous polyps were 'hard to interpret.' The findings do 'little to improve confidence in clinical execution, as cash burn and dilution risk are top of mind,' he wrote.
